As the US remains the top market for the Indian pharmaceutical industry, experts in India are now expecting opportunities for ...

US Ambassador to India, Eric Garcetti on Friday at the inauguration ceremony of US Consulate office in Bengaluru said that ...

Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

for the insulin facility of Biocon Biologics in Malaysia. This development marks the resolution of a significant regulatory ...

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to end regulatory hurdles for the pharma player.